NorthWest Biotherapeutics Inc (NWBO)

[staccani]

Long, makes sense to me. It is definitively one possibility. I wonder if the difficulty to get a clear understanding of the data is also due to the study design where the first milestone was set at 66 events (deaths) whereas the primary endpoint is Progression Free survival. The two are somehow linked but are not the same. I mean you can have 66 deaths, with maybe more people dying in the placebo group, and yet have more or less the same % of people progressing without reoccurence, just because the timeframe was not long enough to show a significant difference between the placebo group and the treated arm. Wouldn't have made more sense to have interim analyses at set milestones linked to PFS, eg compare % of people in the placebo vs treated arm which show PFS after 24 or 36 months of treatment, considering that the rpimary endpoint is PFS?